Tiny nanowire implant aims to restore sight in rare eye disease
NCT ID NCT05853107
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This pilot study is testing a new retinal implant called AuTNA I in 7 people with retinitis pigmentosa, a genetic condition that causes progressive vision loss. The implant, a tiny array of nanowires placed under the retina, is designed to replace damaged light-sensing cells. Researchers will check safety and measure any vision improvements over one year using eye tests, brain scans, and electrical activity tests.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AuTNA I retinal prosthesis (nanoparticle-decorated titanium dioxide nanowire array device implanted under the retina)
What this could lead to
If successful, this could offer a new way to restore some vision in people with retinitis pigmentosa who have lost sight.
What could go wrong
This is a very early pilot study with only 7 people, so results may not apply widely. The implant is a new device, and risks like surgical complications or lack of vision improvement are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chunhui Jiang
RECRUITINGShanghai, Shanghai Municipality, 200030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••